Prospective evaluation of the hemorrhoid energy treatment for the management of bleeding internal hemorrhoids.
Bleeding hemorrhoids
Constipation
Internal hemorrhoids
Mucus
Painless bleeding
Straining
Journal
World journal of gastrointestinal endoscopy
ISSN: 1948-5190
Titre abrégé: World J Gastrointest Endosc
Pays: United States
ID NLM: 101532474
Informations de publication
Date de publication:
16 Aug 2021
16 Aug 2021
Historique:
received:
16
12
2020
revised:
07
04
2021
accepted:
19
07
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
ppublish
Résumé
The hemorrhoid energy treatment (HET) system is a non-surgical bipolar electrotherapy device, which has previously demonstrated efficacy in the management of bleeding Grade I and II internal hemorrhoids; however, data is limited. To prospectively assess the safety and efficacy of the HET device. This was an IRB-approved prospective study of 73 patients with Grade I or II internal hemorrhoids who underwent HET from March 2016 to June 2019. Patient factors and procedural data were obtained. A post-procedure questionnaire was administered by telephone to all patients at 1-wk and 3-mo following HET to assess for improvement and/or resolution of rectal bleeding and adherence to a stool softener regimen. A chart review was performed to observe recurrent symptoms and durability of response. Statistical analyses were performed using SPSS software (IBM; SPSS Version 25.0). Seventy-three patients underwent HET during the study period. Mean post-HET follow-up was 1.89 years. Complete resolution of bleeding was reported in 65% at 1 wk ( HET is well tolerated, safe and highly effective in the majority of our patients presenting with Grade I and II symptomatic internal hemorrhoids.
Sections du résumé
BACKGROUND
BACKGROUND
The hemorrhoid energy treatment (HET) system is a non-surgical bipolar electrotherapy device, which has previously demonstrated efficacy in the management of bleeding Grade I and II internal hemorrhoids; however, data is limited.
AIM
OBJECTIVE
To prospectively assess the safety and efficacy of the HET device.
METHODS
METHODS
This was an IRB-approved prospective study of 73 patients with Grade I or II internal hemorrhoids who underwent HET from March 2016 to June 2019. Patient factors and procedural data were obtained. A post-procedure questionnaire was administered by telephone to all patients at 1-wk and 3-mo following HET to assess for improvement and/or resolution of rectal bleeding and adherence to a stool softener regimen. A chart review was performed to observe recurrent symptoms and durability of response. Statistical analyses were performed using SPSS software (IBM; SPSS Version 25.0).
RESULTS
RESULTS
Seventy-three patients underwent HET during the study period. Mean post-HET follow-up was 1.89 years. Complete resolution of bleeding was reported in 65% at 1 wk (
CONCLUSION
CONCLUSIONS
HET is well tolerated, safe and highly effective in the majority of our patients presenting with Grade I and II symptomatic internal hemorrhoids.
Identifiants
pubmed: 34512880
doi: 10.4253/wjge.v13.i8.329
pmc: PMC8394182
doi:
Types de publication
Journal Article
Langues
eng
Pagination
329-335Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All authors have no conflict of interest to report.
Références
Dis Colon Rectum. 1995 Jul;38(7):687-94
pubmed: 7607026
Gastroenterology. 1990 Feb;98(2):380-6
pubmed: 2295392
Med Devices (Auckl). 2012;5:89-96
pubmed: 23152714
Surg Innov. 2016 Dec;23(6):581-585
pubmed: 27448595
Clin Colon Rectal Surg. 2016 Mar;29(1):22-9
pubmed: 26929748
Am J Gastroenterol. 2014 Aug;109(8):1141-57; (Quiz) 1058
pubmed: 25022811
Dis Colon Rectum. 1999 Mar;42(3):421-3
pubmed: 10223767
Br J Surg. 2005 Dec;92(12):1481-7
pubmed: 16252313
Int J Colorectal Dis. 2012 Feb;27(2):215-20
pubmed: 21932016
Gastrointest Endosc. 2013 Oct;78(4):649-53
pubmed: 23891414
Updates Surg. 2015 Mar;67(1):3-9
pubmed: 25724281
Dig Surg. 2005;22(1-2):26-33
pubmed: 15838168
Rev Gastroenterol Disord. 2009 Winter;9(1):16-26
pubmed: 19367214